Mobius Therapeutics™ Customers to Advocate Use of Mitosol®

First use of social media platform by Mobius™ supports value proposition to end users.

ST. LOUIS, May 10, 2022 /PRNewswire/ — Mobius Therapeutics™, LLC, a St. Louis-based perioperative ophthalmic pharmaceutical company, will initiate a social media presence featuring interviews and live streaming of customers to support the value proposition of its flagship product, Mitosol®.

“Mitosol® customers have the option to purchase compounded copies of our approved formulation from pharmacies and outsourcing facilities,” said Ed Timm, CEO of Mobius Therapeutics. “Their loyalty to Mitosol® reflects its inherent value to patients and caregivers.  Providers need to hear real world views from their peers, not just company authored advocacy.”

Mitosol® is the only FDA approved formulation of mitomycin-c bearing an ophthalmic indication. With room temperature storage and shelf life of up to 24 months, Mitosol® offers unique flexibility to providers, as its “shelf-ready” status permits on demand utility.

“Real-world voices are indicative of real-world value,” continued Timm. “We must listen to these voices, as they translate marketing into common vernacular. They tell us that with Mitosol®, everyone wins: the patient, the provider, and the American healthcare system.”

About Mobius Therapeutics, LLC:
Mobius Therapeutics is a commercial stage venture focused on sterile perioperative ophthalmic pharmaceuticals. Mitosol® (mitomycin for solution) 0.2 mg/vial, Kit for Ophthalmic Use, is the only formulation of mitomycin-c bearing an ophthalmic indication.  Mobius maintains additional perioperative formulations in commercialization, as well as an active product pipeline. Please see full prescribing information at https://mitosol.com/mitosol-package-insert/.

CONTACT:
Ed Timm
Mobius Therapeutics, LLC
314-615-6932
Ed.Timm@MobiusTx.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/mobius-therapeutics-customers-to-advocate-use-of-mitosol-301542636.html

SOURCE Mobius Therapeutics, LLC